Announcement Planned by Ontario Ministry of Economic Development and Trade



    BELLEVILLE, ON, Dec. 17 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company, today
announced that the Ontario Ministry of Economic Development & Trade has issued
a Media Advisory related to an announcement that will take place tomorrow at
Bioniche's Belleville, Ontario facility.
    The Advisory, entitled, "McGuinty Government to Announce New Investment
in Advanced Manufacturing; Boosts Life Sciences Innovation, Job Creation in
Belleville", was issued this morning. The Advisory reads as follows: "Sandra
Pupatello, Minister of Economic Development and Trade, together with Leona
Dombrowsky, Minister of Agriculture, Food and Rural Affairs, will announce a
new investment under the government's Advanced Manufacturing Investment
Strategy (AMIS) that will boost manufacturing excellence and innovation in
Belleville."

    About Bioniche Life Sciences Inc.

    Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
200 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. Bioniche has been named one of Canada's Top Ten Life Sciences
Companies for 2008. For more information, please visit www.Bioniche.com.

    Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00013159E




For further information:

For further information: Jennifer Shea, Corporate Communications &
Investor Relations Manager, Bioniche Life Sciences Inc., Telephone: (613)
966-8058, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com

Organization Profile

Telesta Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890